Open AccessAlteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer
Author(s) -
Kazue Yoneda,
Taiji Kuwata,
Masatoshi Kanayama,
Masataka Mori,
Toshinori Kawanami,
Kazuhiro Yatera,
Takayuki Ohguri,
Masanori Hisaoka,
Toshiyuki Nakayama,
Fumihiro Tanaka
Publication year - 2019
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-019-0541-3
Subject(s) - medicine , durvalumab , tumor infiltrating lymphocytes , cd8 , radiation therapy , lung cancer , oncology , stromal cell , pd l1 , chemotherapy , immunotherapy , cancer , immune system , immunology , nivolumab
Consolidation treatment with an anti-PD-L1 antibody, durvalumab, following concurrent chemo-radiotherapy (cCRT) has become a new standard of care for locally advanced non-small cell lung cancer (NSCLC). The rationale of PD-L1 blockade after cCRT is based on preclinical evidence suggesting that chemotherapy and radiotherapy up-regulate tumoural PD-L1 expression, which has not been shown in clinical studies.